P501: CLI120-001 PHASE1B DOSE ESCALATION STUDY OF RVU120 IN PATIENTS WITH AML OR HIGH RISK MDS SAFETY AND EFFICACY DATA UPDATE
Main Authors: | C. Abboud, Z. Jan Maciej, G. Borthakur, S. Solomon, B. Howard, T. Bradley, E. Mouhayar, N. Angelosanto, H. Nogai, A. Glasmacher, R. Dudziak, K. Brzozka, T. Rzymski, P. Littlewood, E.-L. Maranda |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000844892.61844.a1 |
Similar Items
-
P526: SAFETY AND EFFICACY UPDATE FROM CLI120-001: A PHASE1B DOSE ESCALATION STUDY IN RELAPSE-REFRACTORY ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASIA
by: Ewa Lech-Marańda, et al.
Published: (2023-08-01) -
P450: PRECLINICAL AND CLINICAL SIGNS OF RVU120 EFFICACY, A SPECIFIC CDK8/19 INHIBITOR IN DNMT3A MUTATION POSITIVE AML AND HR-MDS
by: U. Pakulska, et al.
Published: (2022-06-01) -
Inherited predisposition to MDS/AML
by: Ana Rio Machin, et al.
Published: (2018-06-01) -
Alignment of RVU Targets With Operating Room Block Time
by: Saieesh A. Rao, MD, et al.
Published: (2023-03-01) -
Determination of the thermal stability of the fullerene dimers C 120, C120O, and C120O2
by: Zhang, J, et al.
Published: (2006)